Race Oncology Limited (ASX: RAC)

Market Cap	243.78M
Revenue (ttm)	4.00M
Net Income (ttm)	-13.82M
Shares Out	170.47M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,377
Open	1.415
Previous Close	1.360
Day's Range	1.390 - 1.435
52-Week Range	0.640 - 2.090
Beta	1.74
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2024

About Race Oncology

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In 2024, Race Oncology's revenue was 4.00 million, an increase of 27.73% compared to the previous year's 3.13 million. Losses were -13.82 million, 39.3% more than in 2023.